美股异动 | 旗下药物获得重大突破 Kymera Therapeutics(KYMR.US)大涨超40%

Core Insights - Kymera Therapeutics (KYMR.US) experienced a significant stock price increase of over 40%, reaching a historical high of $95.66, following positive trial results for its drug KT-621 [1] Group 1: Drug Trial Results - KT-621 demonstrated deep STAT6 degradation in both 100 mg and 200 mg dosage groups, with median degradation rates of 94% in skin and 98% in blood, indicating strong translational capability from healthy volunteers to atopic dermatitis (AD) patients [1] - The drug showed significant reductions in disease-related type 2 biomarkers in blood, including a 74% median decrease in thymus-activated chemokine (TARC) compared to baseline levels in patients similar to those in the dupilumab AD study, along with reductions in Eotaxin-3, IL-31, IgE, and core type 2 inflammation genes in skin lesions [1] Group 2: Ongoing and Future Trials - The ongoing BROADEN2 Phase 2b trial for moderate to severe AD is expected to yield data by mid-2027 [1] - A Phase 2b BREADTH trial targeting moderate to severe asthma patients is planned to commence in the first quarter of 2026 [1]